Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer

Namrata Vijayvergia, Ranee Mehra

Research output: Contribution to journalReview article

Abstract

The revolution in individualized therapy for patients with advanced non-small cell lung cancer (NSCLC) has seen the emergence of a number of molecularly targeted therapies for distinct patient molecular subgroups. Activating anaplastic lymphoma kinase (ALK)-gene rearrangement has been detected in 3-7 % of NSCLC cases, and the ALK inhibitor crizotinib is now an approved treatment for patients with tumors harboring this event. However, resistance to ALK-targeted therapies is a ubiquitous problem in the management of advanced ALK-positive NSCLC and can be mediated by secondary kinase mutations or the activation of compensatory alternative oncogenic drivers. New, more potent ALK inhibitors such as ceritinib (LDK378), alectinib (CH5424802), and AP26113 are now emerging, together with an increased knowledge of the molecular basis of resistance. There is a need to evaluate the optimal clinical application of these new agents, either as sequential therapies or in combination with other targeted agents, to combat resistance and prolong survival in patients with ALK-positive NSCLC. The remarkable clinical activity of ALK inhibitors also emphasizes the importance of optimal diagnostic testing algorithms, to ensure that all eligible patients receive these breakthrough therapies.

Original languageEnglish (US)
Pages (from-to)437-446
Number of pages10
JournalCancer Chemotherapy and Pharmacology
Volume74
Issue number3
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Cells
Therapeutics
Gene Rearrangement
anaplastic lymphoma kinase
Tumors
Phosphotransferases
Genes
Chemical activation
Mutation
Survival
Testing
Neoplasms

Keywords

  • ALK inhibitors
  • Anaplastic lymphoma kinase
  • Diagnostics
  • Non-small cell lung cancer
  • Resistance

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer. / Vijayvergia, Namrata; Mehra, Ranee.

In: Cancer Chemotherapy and Pharmacology, Vol. 74, No. 3, 2014, p. 437-446.

Research output: Contribution to journalReview article

@article{7a72d327191e490a92a37108fdb7b5ac,
title = "Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer",
abstract = "The revolution in individualized therapy for patients with advanced non-small cell lung cancer (NSCLC) has seen the emergence of a number of molecularly targeted therapies for distinct patient molecular subgroups. Activating anaplastic lymphoma kinase (ALK)-gene rearrangement has been detected in 3-7 {\%} of NSCLC cases, and the ALK inhibitor crizotinib is now an approved treatment for patients with tumors harboring this event. However, resistance to ALK-targeted therapies is a ubiquitous problem in the management of advanced ALK-positive NSCLC and can be mediated by secondary kinase mutations or the activation of compensatory alternative oncogenic drivers. New, more potent ALK inhibitors such as ceritinib (LDK378), alectinib (CH5424802), and AP26113 are now emerging, together with an increased knowledge of the molecular basis of resistance. There is a need to evaluate the optimal clinical application of these new agents, either as sequential therapies or in combination with other targeted agents, to combat resistance and prolong survival in patients with ALK-positive NSCLC. The remarkable clinical activity of ALK inhibitors also emphasizes the importance of optimal diagnostic testing algorithms, to ensure that all eligible patients receive these breakthrough therapies.",
keywords = "ALK inhibitors, Anaplastic lymphoma kinase, Diagnostics, Non-small cell lung cancer, Resistance",
author = "Namrata Vijayvergia and Ranee Mehra",
year = "2014",
doi = "10.1007/s00280-014-2517-6",
language = "English (US)",
volume = "74",
pages = "437--446",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer

AU - Vijayvergia, Namrata

AU - Mehra, Ranee

PY - 2014

Y1 - 2014

N2 - The revolution in individualized therapy for patients with advanced non-small cell lung cancer (NSCLC) has seen the emergence of a number of molecularly targeted therapies for distinct patient molecular subgroups. Activating anaplastic lymphoma kinase (ALK)-gene rearrangement has been detected in 3-7 % of NSCLC cases, and the ALK inhibitor crizotinib is now an approved treatment for patients with tumors harboring this event. However, resistance to ALK-targeted therapies is a ubiquitous problem in the management of advanced ALK-positive NSCLC and can be mediated by secondary kinase mutations or the activation of compensatory alternative oncogenic drivers. New, more potent ALK inhibitors such as ceritinib (LDK378), alectinib (CH5424802), and AP26113 are now emerging, together with an increased knowledge of the molecular basis of resistance. There is a need to evaluate the optimal clinical application of these new agents, either as sequential therapies or in combination with other targeted agents, to combat resistance and prolong survival in patients with ALK-positive NSCLC. The remarkable clinical activity of ALK inhibitors also emphasizes the importance of optimal diagnostic testing algorithms, to ensure that all eligible patients receive these breakthrough therapies.

AB - The revolution in individualized therapy for patients with advanced non-small cell lung cancer (NSCLC) has seen the emergence of a number of molecularly targeted therapies for distinct patient molecular subgroups. Activating anaplastic lymphoma kinase (ALK)-gene rearrangement has been detected in 3-7 % of NSCLC cases, and the ALK inhibitor crizotinib is now an approved treatment for patients with tumors harboring this event. However, resistance to ALK-targeted therapies is a ubiquitous problem in the management of advanced ALK-positive NSCLC and can be mediated by secondary kinase mutations or the activation of compensatory alternative oncogenic drivers. New, more potent ALK inhibitors such as ceritinib (LDK378), alectinib (CH5424802), and AP26113 are now emerging, together with an increased knowledge of the molecular basis of resistance. There is a need to evaluate the optimal clinical application of these new agents, either as sequential therapies or in combination with other targeted agents, to combat resistance and prolong survival in patients with ALK-positive NSCLC. The remarkable clinical activity of ALK inhibitors also emphasizes the importance of optimal diagnostic testing algorithms, to ensure that all eligible patients receive these breakthrough therapies.

KW - ALK inhibitors

KW - Anaplastic lymphoma kinase

KW - Diagnostics

KW - Non-small cell lung cancer

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=84907598750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907598750&partnerID=8YFLogxK

U2 - 10.1007/s00280-014-2517-6

DO - 10.1007/s00280-014-2517-6

M3 - Review article

C2 - 25135623

AN - SCOPUS:84907598750

VL - 74

SP - 437

EP - 446

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -